Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Cold Tumors: A Therapeutic Challenge for Immunotherapy.

Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, Caux C, Depil S.

Front Immunol. 2019 Feb 8;10:168. doi: 10.3389/fimmu.2019.00168. eCollection 2019. Review.

2.

Pattern recognition receptors: immune targets to enhance cancer immunotherapy.

Shekarian T, Valsesia-Wittmann S, Brody J, Michallet MC, Depil S, Caux C, Marabelle A.

Ann Oncol. 2017 Aug 1;28(8):1756-1766. doi: 10.1093/annonc/mdx179. Review.

PMID:
28444111
3.

In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer.

Clémenceau B, Valsesia-Wittmann S, Jallas AC, Vivien R, Rousseau R, Marabelle A, Caux C, Vié H.

J Immunol Res. 2015;2015:482089. doi: 10.1155/2015/482089. Epub 2015 Nov 17.

4.

Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity.

Duong MN, Cleret A, Matera EL, Chettab K, Mathé D, Valsesia-Wittmann S, Clémenceau B, Dumontet C.

Breast Cancer Res. 2015 Apr 24;17:57. doi: 10.1186/s13058-015-0569-0.

5.

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.

Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vély F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, Perri P, Tchirkov A, Matta J, Lapierre V, Shekarian T, Valsesia-Wittmann S, Commo F, Prada N, Poirier-Colame V, Bressac B, Cotteret S, Brugieres L, Farace F, Chaput N, Kroemer G, Valteau-Couanet D, Zitvogel L.

Sci Transl Med. 2015 Apr 15;7(283):283ra55. doi: 10.1126/scitranslmed.aaa2327.

PMID:
25877893
6.

Paradigm shift in oncology: targeting the immune system rather than cancer cells.

Shekarian T, Valsesia-Wittmann S, Caux C, Marabelle A.

Mutagenesis. 2015 Mar;30(2):205-11. doi: 10.1093/mutage/geu073. Review.

PMID:
25688113
7.

Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies.

Duong MN, Matera EL, Mathé D, Evesque A, Valsesia-Wittmann S, Clémenceau B, Dumontet C.

MAbs. 2015;7(1):192-8. doi: 10.4161/19420862.2015.989020.

8.

TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.

Selmi A, de Saint-Jean M, Jallas AC, Garin E, Hogarty MD, Bénard J, Puisieux A, Marabelle A, Valsesia-Wittmann S.

Cancer Lett. 2015 Feb 1;357(1):412-418. doi: 10.1016/j.canlet.2014.11.056. Epub 2014 Dec 1.

PMID:
25475555
9.

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia.

Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee D, Yvon E, Finney H, Lawson A, Brenner M, Biondi A, Biagi E, Rousseau R.

Adv Hematol. 2012;2012:683065. doi: 10.1155/2012/683065. Epub 2012 Jan 5.

10.

Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells.

Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, Barshack I, Brait M, Sidransky D, Domany E, Rotter V.

Cell Death Differ. 2011 Feb;18(2):271-81. doi: 10.1038/cdd.2010.94. Epub 2010 Aug 6.

11.

Upstream ORF affects MYCN translation depending on exon 1b alternative splicing.

Besançon R, Valsesia-Wittmann S, Locher C, Delloye-Bourgeois C, Furhman L, Tutrone G, Bertrand C, Jallas AC, Garin E, Puisieux A.

BMC Cancer. 2009 Dec 17;9:445. doi: 10.1186/1471-2407-9-445.

12.

Cancer stem cells: the emerging challenge of drug targeting.

Besançon R, Valsesia-Wittmann S, Puisieux A, Caron de Fromentel C, Maguer-Satta V.

Curr Med Chem. 2009;16(4):394-416. Review.

PMID:
19199913
13.

Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence.

Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron de Fromentel C, Puisieux A.

Cancer Cell. 2008 Jul 8;14(1):79-89. doi: 10.1016/j.ccr.2008.06.005.

14.

[Cancer cells escape from failsafe programs in a simple Twist].

Puisieux A, Valsesia-Wittmann S.

Bull Cancer. 2006 Mar 1;93(3):251-6. Review. French.

15.

A twist for survival and cancer progression.

Puisieux A, Valsesia-Wittmann S, Ansieau S.

Br J Cancer. 2006 Jan 16;94(1):13-7. Review.

16.

Genome-wide analysis of gene expression in neuroblastomas detected by mass screening.

Krause A, Combaret V, Iacono I, Lacroix B, Compagnon C, Bergeron C, Valsesia-Wittmann S, Leissner P, Mougin B, Puisieux A.

Cancer Lett. 2005 Jul 8;225(1):111-20. Epub 2004 Dec 8.

17.

Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.

Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, Combaret V, Krause A, Leissner P, Puisieux A.

Cancer Cell. 2004 Dec;6(6):625-30.

18.

BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells.

el-Ghissassi F, Valsesia-Wittmann S, Falette N, Duriez C, Walden PD, Puisieux A.

Oncogene. 2002 Oct 3;21(44):6772-78.

19.
20.
21.

Receptor co-operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding.

Valsesia-Wittmann S, Morling FJ, Hatziioannou T, Russell SJ, Cosset FL.

EMBO J. 1997 Mar 17;16(6):1214-23. Erratum in: EMBO J 1997 Jul 1;16(13):4153.

22.
23.

Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors.

Valsesia-Wittmann S, Drynda A, Deléage G, Aumailley M, Heard JM, Danos O, Verdier G, Cosset FL.

J Virol. 1994 Jul;68(7):4609-19.

Supplemental Content

Loading ...
Support Center